Dr. Zain Discusses Ongoing Trials in T-Cell Lymphomas

Jasmine Zain, MD
Published Online: Thursday, December 19, 2013
Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

At the Center for the Lymphoid Malignancies, researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas. The two agents approved in this space, vorinostat and romidepsin, both have response rates close to 30%. Zain says the goal is to improve on these response rates in the relapsed setting and even move them to the upfront setting.

Activity remains to be seen in a phase I trial looking at romidepsin and 5-azacytidine. In another trial, activity is just being observed with pralatrexate and romidepsin. Both trials are open and enrolling.

Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
More Reading
$auto_registration$